BioProtect Launches an International Multi-Center Clinical Study Following FDA IDE approval

January 9, 2018
FDA has granted Investigational Device Exemption approval (IDE) to conduct a pivotal clinical study examining the use of the ProSpace™ Balloon System to prevent rectal toxicity following prostate cancer radiotherapy   TEL AVIV, Israel, January 9, 2018 /PRNewswire/ — BioProtect, the technology leader in biodegradable balloon spacers protecting normal tissue during radiation therapy, announced the launch of its clinical trial following Investigational…
Read More

BioProtect Establishes a New Subsidiary in Germany

January 10, 2018
BioProtect, Ltd, a leader in balloon spacers for radiation oncology , has established a new subsidiary in Germany called BioProtect GmbH, a company that is duly incorporated with offices located in the city of Hamburg This new subsidiary will help BioProtect expand in a large country that recently established a reimbursement code OPS-code 5-609-91 related to the spacer implantation procedure for…
Read More

IDE application approved by FDA

November 14, 2017
FDA has granted investigational Device Exemption approval (IDE) to conduct a pivotal clinical study Examining the Use of the ProSpaceTM balloon rectal spacer to prevent GI toxicity following prostate cancer radiotherapy. The company will soon start enrollment for its first large-scale international multi-center clinical study following FDA’s investigational Device Exemption (IDE).
Read More